류마티스관절염 환자의 심혈관 질환 및 당뇨병 위험분석: a propensity score analysis

유기연 한국임상약학회 2019 한국임상약학회지 Vol.29 No.2

Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests as joint damage or athletic disability via sustained inflammation of the synovial membrane. The risk of cardiovascular disease (CVD) is higher in RA patients. This study aimed at evaluating the association between CVD comorbidities and RA by comparing a pharmacotherapy group with a nonpharmacotherapy group. Methods: Patient sample data from the Health Insurance Review and Assessment Service (HIRA-NPS- 2016) were used. Inverse probability of treatment weighting (IPTW) using the propensity score was used to minimize the differences in patient characteristics. Logistic regression analysis was used to evaluate the risk of CVD comorbidities. Results: The analyses included 1,207,213 patients, of which 33,122 (2.8%) had RA. The odds ratios (OR) of CVD comorbidities were increased in RA patients; ischemic heart disease (IHD: OR 1.75; 95% CI 1.73, 1.77), cerebral infarction (CERI: OR 1.28; 95% CI 1.26, 1.30), hypertension (HTN: OR 1.44; 95% CI 1.43, 1.45), diabetes mellitus (DM: OR 2.04; 95% CI 2.03, 2.06), and dyslipidemia (DL: OR 3.49; 95% CI 3.47, 3.51). The ORs of IHD, CERI, HTN, and DM in the traditional DMARD and biologic treatment groups were decreased, compared with those in the non-pharmacotherapy group. Conclusions: Thus, CVD risk was higher in RA patients, considering age, sex, and socioeconomic status. Appropriate pharmacotherapy could decrease the risk of CVD comorbidities in RA patients.

사람과 건축 이야기 - 과거를 회상하며

유기연,Yu, Kiyeon 대한건축사협회 2023 建築士 Vol.654 No.-

만성골수성백혈병 치료제의 효과: 메타분석

유기연 한국병원약사회 2013 병원약사회지 Vol.30 No.4

Chronic myeloid leukemia (CML) is one of the myeloproliferative disorders which is associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in a BCR-ABL gene. This abnormal gene produces a specific product BCR-ABL tyrosine kinase. Therefore, tyrosine kinase inhibitors (TKIs) could be used for long term controls of CML progression for most patients, and these have good tolerance and low adverse drug reaction rates. The present study was performed to evaluate the efficacy and safety of imatinib, dasatinib, and nilotinib as a first, second, third line therapy for CML. This meta-analysis was taken on August 31st 2012, the Medline and Embase searches were used to access the appropriate studies. Twenty-six studies, which suggested the cytogenetic, hematologic and molecular responses, were selected for this analysis. Dasatinib (0.839, 95% CI: 0.790-0.878) and nilotinib (0.797, 95% CI: 0.749-0.838) were analyzed as to having superior cytogenetic responses for patients of newly diagnosed CML-CP (chronic phase) when compared to imatinib (0.676, 95% CI: 0.749-0.838). The ADR, however were less shown in the imatinib group as compared to the second generation TKIs. For imatinib resistant or intolerant patients, the dasatinib 100 mg qd (CCgR 95% CI: 0.474-0.597, CHR 95% CI: 0.877-0.953, MMolR 95% CI: 0.253-0.376) were analyzed with the most suitable therapy option as compared to dasatinib 70 mg (CCgR 95% CI: 0.372-0.429, CHR 95% CI: 0.489-0.561, MMolR 95% CI: 0.274-0.410) or nilotinib 400 mg bid (CCgR 95% CI: 0.324-0.382, CHR 95% CI: 0.587-0.673, MMolR 95% CI: 0.220-0.289). In the third line therapy for CML, there are no significant differences between dasatinib 70 mg bid and nilotinib 400 mg bid groups.

Berberry extract reduces neuronal damage and N-methyl-D-aspartate receptors immunoreactivities in the gerbil hippocampus after transient forebrain ischemia

유기연,황인구,이승욱,임병우,강태천,김동우,김상무,이현용,김종대,원무호 한국실험동물학회 2005 한국실험동물학회 학술발표대회 논문집 Vol.2005 No.-

식품의약품안전청에 보고된 심혈관계 약물유해반응의 특성 분석

유기연,조혜경,이숙향 한국임상약학회 2012 한국임상약학회지 Vol.22 No.1

임산부의 약물 인식 및 복약 순응도 조사연구

유기연 한국임상약학회 2013 한국임상약학회지 Vol.23 No.3

치매환자에서의 심혈관계 약물사용 분석

유기연 한국임상약학회 2017 한국임상약학회지 Vol.27 No.3

Background: Dementia is one of important social and economic healthcare issues in the aging age. Therefore, it signifies to analyze the relationship between chronic disease or cardiovascular drug use and the incidence of dementia to establish a basis for increasing or preventing the risk of dementia. The purpose of this study was to investigate the correlation between the prevalence of chronic diseases and the use of cardiovascular drugs in patients diagnosed with dementia. Methods: In this study, we used data from sample of elderly patients from the Health Insurance Review and Assessment Service. We analyzed by logistic regression analysis with age, gender, and medication as covariates. KCD-7 was used to diagnosis of the disease, and drugs were analyzed using ATC codes and Korean standardized drug classification codes. Results: A total of 1,276,331 patients were analyzed in the sample of the elderly population, of which 532,075 (41.7%) were male and 744,256 (58.3%) were female. The patients have the higher risk of dementia in the older, women, and lower socioeconomically status. Cerebral infarction and ischemic heart disease increases risk of dementia. Patients taking statins, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonists (ARB) showed low incidence of dementia. Conclusion: This study has been shown that ACEI, ARB, and statin drugs may associate with lower incidence of Alzheimer's and other dementia except vascular dementia.

Copper chaperone for Cu,Zn-SOD supplement potentates the Cu,Zn-SOD functions of neuroprotective effects against ischemic neuronal damage in the gerbil hippocampus

유기연,음원식,김대원,이승욱,이윤희,강태천,권오신,강정훈,최수영,원무호 한국실험동물학회 2005 한국실험동물학회 학술발표대회 논문집 Vol.2005 No.-

Zizyphus Attenuates Ischemic Damage in the Gerbil Hippocampus via Its Antioxidant Effect

유기연,Hua Li,황인구,Jung Hoon Choi,Choong Hyun Lee,Dae Young Kwon,유시용,김영섭,강일준,신형철,원무호 한국식품영양과학회 2010 Journal of medicinal food Vol.13 No.3

The fruit of Zizyphus jujuba has been used as a traditional Chinese medicinal herb and considered for thousands of years to affect various physiological functions in the body. We obtained a Z. jujuba extract (ZJE) and observed the neuroprotective effects of ZJE against ischemic damage in gerbils that had received repeated oral administrations of ZJE for 10 days. In the ZJE-treated ischemia group, neuronal nuclei (a marker for neurons)-immunoreactive neurons were abundant (58.4% vs. sham group) in the hippocampal CA1 region 4 days after ischemia/reperfusion compared to those in the vehicle-treated ischemia group (11.3%). In addition, ZJE treatment significantly decreased the reactive gliosis of astrocytes and microglia in the CA1 region compared to that in the vehicle-treated group 4 days after ischemia/reperfusion. Immunoreactivities of Cu,Zn-superoxide dismutase (SOD1) and brain-derived neurotrophic factor in the ZJE-treated ischemia group were higher those in the vehicle-treated ischemia group 4 days after ischemia/reperfusion. In addition, in the ZJE-treated ischemia group, levels of hydroxynonenal, an indicator of lipid peroxidation, were much lower than those in the vehicle-treated ischemia group after ischemia/reperfusion. These results suggest that the repeated supplements of ZJE can protect neurons from ischemic damage via up-regulation of SOD1 and reduction of lipid peroxidation in the ischemic hippocampal CA1 region.

식품의약품안전청 약물유해반응 보고자료 분석

유기연,이숙향 한국임상약학회 2011 한국임상약학회지 Vol.21 No.2

In order to minimize such adverse drug reactions, governments and international organs have been on the watch for them. Also in South Korea, a system has been established in order that adverse drug reactions may be reported to Korea Food and Drug Administration(KFDA). This study is to analyze drugs to cause adverse reactions, the adverse reactions and patients concerned on the authority of the data of Korea FDA, which is expected to be the preliminary data on preventable adverse reactions. This study was conducted on the 74,037 cases of adverse drug reactions reported to Korea FDA between January 2007 and June 2010. Fentanyl, iopromide and tramadol caused adverse reactions with high frequencies. Oseltamivir showed a high frequency between 2009 and 2010 due to the influence of the new influenza A. Also, OTC drugs accounted for approximately 5% of the adverse reactions. In 2009, adverse drug reactions remarkably increased (2,106 cases; 10.1%) in infants and children due to the new influenza-A(H1N1). The patients aged between 31 and 64 accounted for approximately 55% during the given period. There was no significant intergender difference. In relation to regions, the adverse reactions most frequently occurred in the gastrointestinal system and the integumentary system for three and half years. In addition to anticancer drugs and immunosuppressive drugs that are known to cause adverse reactions frequently, not a few of OTC drugs and external preparations caused such reactions. In particular, the drugs containing specific ingredients caused adverse reactions more frequently than others from 2007 until the first half of 2010. It is advisable for prescribers to acquaint themselves with such adverse reactions and to prescribe drugs other than them. They also have need to sensibly cope with adverse drug reactions just in case they have no substitute drugs. In addition, patients also need to be trained to understand possible adverse reactions in order that they can sensibly accommodate them or choose healthcare services. The results of this study are expected to be helpful to minimize adverse drug reactions.